NASDAQ:SOPH SOPHiA GENETICS - SOPH Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding SOPHiA GENETICS SA Please log in to your account or sign up in order to add this asset to your watchlist. $4.13 -0.29 (-6.56%) (As of 03/24/2023 03:31 PM ET) Add Compare Share Share Today's Range$4.13▼$4.5050-Day Range$2.27▼$5.4952-Week Range$1.68▼$8.44Volume89,318 shsAverage Volume137,073 shsMarket Capitalization$261.59 millionP/E RatioN/ADividend YieldN/APrice Target$6.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media SOPHiA GENETICS MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside51.5% Upside$6.33 Price TargetShort InterestHealthy0.08% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.12Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.06) to ($0.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.12 out of 5 starsMedical Sector436th out of 989 stocksBiological Products, Except Diagnostic Industry73rd out of 166 stocks 3.3 Analyst's Opinion Consensus RatingSOPHiA GENETICS has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.33, SOPHiA GENETICS has a forecasted upside of 51.5% from its current price of $4.18.Amount of Analyst CoverageSOPHiA GENETICS has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.08% of the float of SOPHiA GENETICS has been sold short.Short Interest Ratio / Days to CoverSOPHiA GENETICS has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SOPHiA GENETICS has recently decreased by 17.70%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSOPHiA GENETICS does not currently pay a dividend.Dividend GrowthSOPHiA GENETICS does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SOPH. Previous Next 2.8 News and Social Media Coverage News SentimentSOPHiA GENETICS has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for SOPHiA GENETICS this week, compared to 1 article on an average week.Search Interest2 people have searched for SOPH on MarketBeat in the last 30 days. MarketBeat Follows2 people have added SOPHiA GENETICS to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SOPHiA GENETICS insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.88% of the stock of SOPHiA GENETICS is held by insiders.Percentage Held by InstitutionsOnly 31.03% of the stock of SOPHiA GENETICS is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SOPHiA GENETICS are expected to grow in the coming year, from ($1.06) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SOPHiA GENETICS is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SOPHiA GENETICS is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSOPHiA GENETICS has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About SOPHiA GENETICS (NASDAQ:SOPH) StockSOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.Read More Receive SOPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SOPHiA GENETICS and its competitors with MarketBeat's FREE daily newsletter. Email Address SOPH Stock News HeadlinesMarch 22, 2023 | marketwatch.comAI Medicine Software Market 2023 Size Industry, Current Trends, Demand and Size Share Estimation by 2029 with Top PlayersMarch 22, 2023 | marketwatch.comPrecision Medicine Software Market Size by 2031March 24, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastMarch 21, 2023 | marketwatch.comGenetic Testing for Cancer Risk Market Future Trends Outlook 2023, and Forecast to 2029 | Myriad Genetics, Inc., Invitae CorporationMarch 21, 2023 | finance.yahoo.comSOPHiA GENETICS SA (NASDAQ:SOPH) surges 23%; individual investors who own 44% shares profited along with institutionsMarch 17, 2023 | finance.yahoo.comSOPHiA GENETICS SA (SOPH) Surges 13.0%: Is This an Indication of Further Gains?March 16, 2023 | finance.yahoo.comSOPHiA GENETICS SA (SOPH) Just Flashed Golden Cross Signal: Do You Buy?March 14, 2023 | finance.yahoo.comSOPHiA GENETICS and Agilent Partner on Comprehensive Solution for Cancer AnalysisMarch 24, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...March 9, 2023 | finance.yahoo.comSOPHiA GENETICS SA (NASDAQ:SOPH) Q4 2022 Earnings Call TranscriptMarch 7, 2023 | finanznachrichten.deSOPHiA GENETICS SA: SOPHiA GENETICS Reports Fourth Quarter and Year End 2022 Financial ResultsMarch 7, 2023 | msn.comSOPHiA Genetics Non-GAAP EPS of -$0.17 beats by $0.13, revenue of $13.38M beats by $0.46MMarch 7, 2023 | finance.yahoo.comSOPHiA GENETICS Reports Fourth Quarter and Year End 2022 Financial ResultsMarch 7, 2023 | finance.yahoo.comSOPHiA GENETICS SA (SOPH) Reports Q4 Loss, Tops Revenue EstimatesMarch 7, 2023 | msn.comSupreme Court rules no genetic tests to find origin of wrongly implanted embryoMarch 6, 2023 | markets.businessinsider.comHere's what Wall Street expects from SOPHiA GENETICS SA's earnings reportMarch 6, 2023 | finance.yahoo.comUniversity of Arkansas for Medical Sciences Will Use SOPHiA GENETICS to Advance Clinical Research for Blood CancersMarch 3, 2023 | finance.yahoo.comSOPHiA GENETICS Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2023March 1, 2023 | marketwatch.comNGS Informatics and Clinical Genomics Market Industry Analysis, Estimates Size and Projections by 2029March 1, 2023 | reuters.comS.Africa's Aspen set for deals to revive idled production linesMarch 1, 2023 | finance.yahoo.comSOPHiA GENETICS and QIAGEN Forge Partnership to Combine Strengths in Next-generation SequencingMarch 1, 2023 | finance.yahoo.comQiagen partners with Sophia Genetics on next-generation sequencing kitsMarch 1, 2023 | seekingalpha.comSOPH SOPHiA GENETICS SAFebruary 28, 2023 | finance.yahoo.comSynergy Laboratories Taps SOPHiA GENETICS Technology for New Cancer Profiling SolutionFebruary 23, 2023 | finance.yahoo.comSOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full Year of Fiscal 2022 on March 7, 2023February 15, 2023 | marketwatch.comHereditary Testing Market Five-year Assessment with Latest Technology Analysis [113+ Pages Report]February 13, 2023 | finance.yahoo.comSOPHiA GENETICS Expands Partnership With AstraZeneca to Include Multimodal Approaches for Cancer Drug DevelopmentSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SOPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SOPHiA GENETICS and its competitors with MarketBeat's FREE daily newsletter. Email Address SOPH Company Calendar Last Earnings11/10/2021Today3/24/2023Next Earnings (Estimated)5/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SOPH CUSIPN/A CIK1840706 Webwww.sophiagenetics.com Phone41-21-694-1060FaxN/AEmployees518Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.33 High Stock Price Forecast$11.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+53.3%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,450,000.00 Net Margins-183.87% Pretax Margin-184.16% Return on Equity-39.48% Return on Assets-32.72% Debt Debt-to-Equity RatioN/A Current Ratio7.32 Quick Ratio7.13 Sales & Book Value Annual Sales$47.56 million Price / Sales5.50 Cash FlowN/A Price / Cash FlowN/A Book Value$3.16 per share Price / Book1.31Miscellaneous Outstanding Shares63,340,000Free Float60,247,000Market Cap$261.59 million OptionableNot Optionable Beta0.88 Key ExecutivesDr. Jurgi Camblong M.B.A. (Age 44)Ph.D., Co-Founder, CEO & Director Mr. Ross Jordan Muken B.Sc. (Age 43)Sr. VP & CFO Mr. Abhimanyu VermaSr. VP & CTODr. Zhenyu Xu Ph.D. (Age 41)Sr. VP & Chief Scientific Officer Jennifer PottageHead of Investor RelationsMr. Daan van Well L.L.M. (Age 49)M.B.A., Sr. VP, Chief Legal Officer & Gen. Counsel Ms. Manuela Da Silva Valente B.A. (Age 53)Sr. VP & Chief People Officer Dr. Thierry ColinSr. VP of Radiomics Bus. AreaDr. Philippe Menu M.B.A. (Age 42)M.D., Ph.D., Sr. VP & Chief Medical Officer Ms. Lara HashimotoSr. VP & Chief Bus. OfficerMore ExecutivesKey CompetitorsOutlook TherapeuticsNASDAQ:OTLKCaribou BiosciencesNASDAQ:CRBUKodiak SciencesNASDAQ:KODSutro BiopharmaNASDAQ:STROVectivBioNASDAQ:VECTView All CompetitorsInstitutional OwnershipBank Pictet & Cie Asia Ltd.Bought 4,600 shares on 2/17/2023Ownership: 0.109%General Electric Co.Bought 1,111,111 shares on 2/15/2023Ownership: 1.754%Millennium Management LLCBought 10,876 shares on 2/15/2023Ownership: 0.418%Morgan StanleySold 424,093 shares on 2/15/2023Ownership: 0.031%Price T Rowe Associates Inc. MDSold 40,240 shares on 2/14/2023Ownership: 1.445%View All Institutional Transactions SOPH Stock - Frequently Asked Questions Should I buy or sell SOPHiA GENETICS stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SOPHiA GENETICS in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SOPH shares. View SOPH analyst ratings or view top-rated stocks. What is SOPHiA GENETICS's stock price forecast for 2023? 3 equities research analysts have issued twelve-month target prices for SOPHiA GENETICS's stock. Their SOPH share price forecasts range from $2.00 to $11.00. On average, they predict the company's stock price to reach $6.33 in the next twelve months. This suggests a possible upside of 53.3% from the stock's current price. View analysts price targets for SOPH or view top-rated stocks among Wall Street analysts. How have SOPH shares performed in 2023? SOPHiA GENETICS's stock was trading at $2.06 at the beginning of 2023. Since then, SOPH stock has increased by 100.5% and is now trading at $4.13. View the best growth stocks for 2023 here. Are investors shorting SOPHiA GENETICS? SOPHiA GENETICS saw a decline in short interest in the month of February. As of February 28th, there was short interest totaling 34,400 shares, a decline of 17.7% from the February 13th total of 41,800 shares. Based on an average daily volume of 79,500 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.1% of the company's stock are sold short. View SOPHiA GENETICS's Short Interest. When is SOPHiA GENETICS's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our SOPH earnings forecast. How were SOPHiA GENETICS's earnings last quarter? SOPHiA GENETICS SA (NASDAQ:SOPH) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.38) by $0.08. The business earned $10.36 million during the quarter, compared to the consensus estimate of $10.25 million. SOPHiA GENETICS had a negative net margin of 183.87% and a negative trailing twelve-month return on equity of 39.48%. What ETF holds SOPHiA GENETICS's stock ? BlackRock Future Health ETF holds 619 shares of SOPH stock, representing 0.03% of its portfolio. What guidance has SOPHiA GENETICS issued on next quarter's earnings? SOPHiA GENETICS issued an update on its FY 2023 earnings guidance on Wednesday, March, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $61.83M-, compared to the consensus revenue estimate of $62.57 million. When did SOPHiA GENETICS IPO? (SOPH) raised $234 million in an initial public offering on Friday, July 23rd 2021. The company issued 13,000,000 shares at a price of $17.00-$19.00 per share. What is SOPHiA GENETICS's stock symbol? SOPHiA GENETICS trades on the NASDAQ under the ticker symbol "SOPH." Who are SOPHiA GENETICS's major shareholders? SOPHiA GENETICS's stock is owned by a number of institutional and retail investors. Top institutional investors include Banque Pictet & Cie SA (3.45%), Credit Suisse AG (3.09%), Principal Financial Group Inc. (2.20%), Jennison Associates LLC (1.91%), General Electric Co. (1.75%) and Price T Rowe Associates Inc. MD (1.45%). How do I buy shares of SOPHiA GENETICS? Shares of SOPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is SOPHiA GENETICS's stock price today? One share of SOPH stock can currently be purchased for approximately $4.13. How much money does SOPHiA GENETICS make? SOPHiA GENETICS (NASDAQ:SOPH) has a market capitalization of $261.59 million and generates $47.56 million in revenue each year. The company earns $-87,450,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. How many employees does SOPHiA GENETICS have? The company employs 518 workers across the globe. How can I contact SOPHiA GENETICS? The official website for the company is www.sophiagenetics.com. The company can be reached via phone at 41-21-694-1060. This page (NASDAQ:SOPH) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.